| Literature DB >> 27175979 |
Helena Lund-Palau1, Andrew R Turnbull1,2, Andrew Bush2,3, Emmanuelle Bardin4, Loren Cameron5, Odel Soren6, Natasha Wierre-Gore3, Eric W F W Alton1, Jacob G Bundy3, Gary Connett7, Saul N Faust7, Alain Filloux8, Paul Freemont5, Andy Jones9, Valerie Khoo3, Sandra Morales10, Ronan Murphy1, Rishi Pabary1, Ameze Simbo1, Silke Schelenz11, Zoltan Takats4, Jeremy Webb11, Huw D Williams7, Jane C Davies1,2.
Abstract
Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa occurs early, and although eradication can be achieved following early detection, chronic infection occurs in over 60% of adults with CF. Chronic infection is associated with accelerated disease progression and increased mortality. Extensive research has revealed complex mechanisms by which P. aeruginosa adapts to and persists within the CF airway. Yet knowledge gaps remain, and prevention and treatment strategies are limited by the lack of sensitive detection methods and by a narrow armoury of antibiotics. Further developments in this field are urgently needed in order to improve morbidity and mortality in people with CF. Here, we summarize current knowledge of pathophysiological mechanisms underlying P. aeruginosa infection in CF. Established treatments are discussed, and an overview is offered of novel detection methods and therapeutic strategies in development.Entities:
Keywords: Pseudomonas aeruginosa; airway; antibiotic; biofilm; cystic fibrosis; persistence; sputum
Mesh:
Substances:
Year: 2016 PMID: 27175979 DOI: 10.1080/17476348.2016.1177460
Source DB: PubMed Journal: Expert Rev Respir Med ISSN: 1747-6348 Impact factor: 3.772